


Sanofi Vaccine Pipeline¹

sanofi

The vaccines described in this document are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such vaccines.


Influenza




High-dose, egg-based vaccine expansion of indication to 50+ yrs^{a} (In review)*

- *mRNA vaccine^b (Phase 2)*
- *Adjuvanted egg-based vaccine^c (Phase 1/2)*
- *Recombinant adjuvanted vaccine² (Phase 1/2)*

H5N1 Influenza



Influenza & COVID-19



- *Adjuvanted protein-based combination vaccine^d (Phase 1/2)*
- *Adjuvanted protein-based + egg-based combination vaccine^e (Phase 1/2)*


RSV + HMPV Older Adults

- *mRNA vaccine^f (Phase 1/2)*
- *Protein-based vaccine^g (Phase 1)***

RSV + HMPV + PIV3 Older Adults

- *mRNA vaccine^h (Phase 1)*
- *Protein-based vaccineⁱ (Phase 1)***

Respiratory Syncytial Virus/ Human Metapneumovirus (RSV/HMPV)



Streptococcus pneumoniae




Pneumococcal Disease

- *21-valent conjugate vaccine^j (Phase 3)[†]*

New Generation Rabies Vaccine

- *Purified Vero cell rabies vaccine^k (In review)*

Rabies



Yellow Fever



New Generation Yellow Fever Vaccine


- *Vero cell live-attenuated vaccine^l* (Phase 3)

New Frontiers


Acne vulgaris affects nearly 240 million people globally and occupies a predominant position in the burden of skin diseases among people aged 10–24 years.^{3,4} The estimated prevalence of acne in the *US* is >8 million cases.⁴

- *Therapeutic mRNA vaccine^m* (Phase 1/2)

Cutibacterium acnes



Chlamydia trachomatis




Chlamydia trachomatis is the most common *bacterial sexually transmitted infection*, affecting both males and females. Around 1.5 million new cases were reported in the US in 2024⁵ and up to 85–90% of cases are *asymptomatic*.⁶

- *mRNA vaccineⁿ* (Phase 1/2)

Herpes zoster (Shingles) is estimated to cause >30 million new cases globally each year,⁷ with approximately 1 million cases occurring annually in the US.⁸

- *Adjuvanted protein-based vaccine^{o†}* (Phase 1/2)

Varicella zoster



COVID-19; Coronavirus Disease 2019; H5N1; Hemagglutinin 5, Neuraminidase 1; HMPV, Human Metapneumovirus; mRNA, Messenger Ribonucleic Acid; PIV3, Parainfluenza Virus Type 3; RSV, Respiratory Syncytial Virus; US, United States

*Extension of indication for high-dose from 50 years old. **Acquired by Sanofi in December 2025. †Developed with SK Bioscience. ‡Acquired by Sanofi in February 2026.

References:

1. Sanofi. Our Product Pipeline. Updated April 23, 2026. Accessed July 6, 2026. Available at: <https://www.sanofi.com/en/our-science/our-pipeline>.
2. Becker's Hospital Review. HHS invests \$226M in pandemic flu shot. Accessed July 6, 2026. Available from: <https://www.beckershospitalreview.com/pharmacy/hhs-invests-226m-in-pandemic-flu-shot/>.
3. Ferrari et al. Lancet. 2024;403:2133-2161. Supplementary Appendix 2.
4. Chen H, et al. Br J Dermatol. 2022;186(4):673-683.
5. Centers for Disease Control and Prevention. Sexually transmitted infections surveillance, 2024. Published 2025. Accessed July 6, 2026. <https://www.cdc.gov/sti-statistics/annual/index.html>.
6. Bleck TP. N Engl J Med. 2004;350(24):2516-2525.
7. Kawai K, et al. BMJ Open. 2014;4(6):e004833.
8. Centers for Disease Control and Prevention. About shingles. Accessed July 6, 2026. <https://www.cdc.gov/shingles/about/index.html>.

a: NCT06641180; b: NCT06727058 & NCT06907511; c: NCT06560151; d: NCT06695130; e: NCT06695117; f: NCT06686654, NCT06134648; g: NCT06556147; h: NCT06604767; i: NCT07295028; j: Developed with SK Bioscience; NCT06736041, NCT06975878; k: NCT04127786; l: NCT07103148, NCT07002060, NCT07222059; m: NCT06316297; n: NCT06891417; o: NCT06569823

What diseases are most in need of a vaccine?



Tell us!

This material is for scientific purposes only. The agents mentioned here are investigational and have not been approved by any regulatory agency worldwide for the uses under investigation. No conclusions regarding safety and efficacy should be drawn for such agents. For most up to date information go to Clinicaltrials.gov.